


QUANTUM SI™

---

# Corporate Presentation



# Disclaimer and Other Information

---

## **Forward-looking Statements**

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway, anticipated data and product launches (including Proteus), investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

## **Non-GAAP Financial Measures**


This presentation includes certain non-GAAP financial measures including “adjusted total operating expenses.” Please see Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2025, for further discussion of the Company’s use of non-GAAP financial measures.

# Quantum-Si Highlights

---



**Experienced team + board**  
from leading life  
sciences companies



**Large and growing**  
proteomics market  
opportunity valued at **\$75B+**



**Differentiated core**  
**technology**, patent-  
protected, extensible to wide  
range of proteomics  
applications



**Expanding user base and**  
**published data** with first-to-  
market Platinum<sup>®</sup> Pro system



**Partnerships** in place  
spanning commercialization,  
product development,  
and manufacturing



**Well-capitalized** with cash  
runway into Q2 2028



**Proteus<sup>™</sup> platform** (est.  
YE26) designed to perform  
high-value applications not  
easily addressed with current  
technologies




**Global distribution network**  
**in place**, covering all  
major markets

# Proteins Are the Core of Biological Discoveries Across Many End Markets


---



# Proteome Complexity



# PTMs and Proteoforms are the Next Frontier in Human Health




A **post-translational modification (PTM)** is a chemical change to an amino acid made *after* a protein has been expressed.


**There are hundreds of different types of PTMs.** A handful are of high interest in proteomics due to their high abundance and roles in disease pathways.

**PTMs determine actual protein function** — making them essential for understanding disease mechanisms and therapeutic targets — but have been difficult to study with current proteomics technology.

# The Study of Proteoforms Extends to Many Disease Areas and Thousands of Unique Proteins




**Affinity-based methods** cannot scale to this complexity




**Complete coverage** of the proteome would require tens of thousands or more unique, site-specific affinity reagents



**Only single-molecule protein sequencing** can tackle this complexity



# Proteomics is a Large and Growing Market Poised for Significant Growth



**Large-scale screening studies** designed to identify clinically relevant biomarkers are underway



**Routine use of multiomics** requires creating new data analysis tools, which will require large amounts of training data



**Deep proteoform-level analysis** will be needed to fully define and characterize the biomarkers with highest medical value



**Clinical adoption will grow** and high-resolution technologies will be required for complex disease areas




**The proteome is dynamic** — longitudinal data will be needed (i.e., repeat testing)



**Biothreat surveillance and detection** will require unbiased proteomics technologies like protein sequencing

# Specialized Platforms With High Capital Costs Limit Adoption Outside of Core Labs in Proteomics

---



**Many specialized platforms** needed to fully interrogate the proteome



**Technical tradeoffs** when selecting between the breadth of protein coverage and depth of insights



**High capital costs** with the top-end instruments costing \$1M or more each




**Manual laboratory and data analysis workflows** limit the number of laboratories capable of performing proteomics



# The Customer Data is Clear

Researchers need a breadth of capabilities to answer their biological questions

Number of PTMs Required



■ One ■ Two ■ Three or more




**More than 50** detailed study proposals submitted by prospective customers

**>50%** require three or more types of protein analysis applications

**Detection of two or more PTMs** is required in **>65%** of cases

Number of Unique Applications



■ One ■ Two ■ Three or more

# Moving Beyond the Core Lab: Proteus Will Enable Deep Protein Analysis and Accelerate the Field of Proteomics

---



**Single-molecule protein sequencing** will be the most versatile technology in proteomics — single amino acid variants, broad PTM coverage, and protein-agnostic



**Automation** simplifies laboratory workflow, increases throughput, and minimizes the need for specialized staff



**Affordable**, allowing any lab — anywhere — to be a proteomics core lab



# Current Platform: Platinum<sup>®</sup> Pro

---



## 1 Prepare

Library Prep and Sequencing Kits contain everything you need to prepare peptide libraries for sequencing



## 2 Sequence

Platinum Pro sequences individual peptides by capturing the fluorescent signal from each amino acid



## 3 Analyze

Our analysis software automates the work and provides amino acid-level insights; offline option available for users who can't access the cloud

# Leveraging Platinum Pro for Market Development and Commercial Infrastructure Build for Proteus Launch

---



**Global distribution network in place**, covering all major markets



**Expanding user base** across many market segments including academic, biopharma, defense, and agriculture



**Focusing on independent data generation** to validate technology and deliver publications




**Collaborating** with customers and corporate partners to develop and validate high-value applications




# Publication Pipeline is Growing



Single-amino acid variants associated with disease








Proteoforms relevant to biological interactions




Peptide barcoding




Single-molecule binding kinetics



# Proteus On Track to Far Exceed Platinum Pro at Launch




**Switch from semiconductor to optical architecture** with patterned nanowell array



**Liquid handling automation** dramatically simplifies workflow



**40× more sequencing throughput** per consumable relative to Platinum at initial launch\*



**Run up to 4 samples** in one sequencing run\*



**Proteus development data** is already superior to Platinum, with further improvements expected before launch


# Proteus Next-generation Architecture

## Platinum<sup>®</sup> Pro + 2M Chip

- Integrated semiconductor consumable with **2 million wells**
- Benchtop instrument with manual workflow

## Proteus<sup>™</sup> + KinetIQ<sup>™</sup> Array

- Simple, passive consumable with estimated **80 million wells** at launch
- Benchtop instrument with imaging system
- Superior sequencing performance
- Workflow automation



# The Increased Sequencing Output and Lower Costs of the Nanowell Array is Broadly Enabling

---




**More samples** per run with 40× the output per consumable compared to Platinum Pro



**Deep analysis** of a single sample to address complex mixtures or rare events like variants or PTMs




**Multiplexing** samples to achieve higher throughput and lower costs per sample for cost sensitive applications like protein ID



# Accelerating the Core Sequencing Technology and Analytics to Unlock the Highest-value Applications

---



**Robust PTM detection**  
and multi-PTM profiling



**Sequencing of variable**  
regions of antibodies



**Single-amino acid**  
variant detection



**Biothreat detection**  
and surveillance

# Proteus Automation Greatly Simplifies the Sequencing Workflow and Makes New Lab Startup Even Easier

---



**Over 30** individual reagent tubes to handle to process four samples


**Over 100** pipetting steps per sample



**A single reagent module** per run — simply unbox and load

**Pipette your sample(s)** into the cartridge and hit *Run*

# Milestones on the Path to Proteus Launch in 2026



# Proteus Architecture Supports Our Long-term Platform Roadmap Requirements



**Consumable architecture** scales to billions of wells




**10× sequencing output** from assay improvements alone



**Future instruments** capable of up to 10B reads



**Instrument roadmap** is designed to make NGPS the core technology in proteomics



# QSI is Well-positioned to Build Upon Our First-to-market Advantage and Extend Our Leadership Into the Future

---



**Grow user base with**  
Platinum Pro and  
develop the market for  
Proteus launch



**Execute on**  
**development roadmap**  
to deliver a compelling  
Proteus launch



**Build a partner**  
**ecosystem to**  
accelerate application  
development + deliver  
*sample-to-report*  
workflows



**Extend our technology**  
**lead** through best-in-  
class R&D innovation  
and execution

---

**Q&A**

